Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
In 2016 the Task Force for Cancer Treatment Toxicity was established and a Position Paper on this topic was published.
In spring 2017 we had the idea to move forward and founded a group inside the ESC on Cardio-Oncology. Following on from a Task Force meeting in Barcelona, it was decided to officially ask the constitution of an ESC Council of Cardio-Oncology. In August 2018 the General Assembly of the ESC definitively approved the Council of Cardio Oncology (CCO).
In the coming years there will probably be a Cardio-Oncology ‘epidemic’ due to either the growing population of cancer survivors, the increasing number of patients aged over 65 who need chronic cancer therapy and the high frequency of cancer therapy induced CVDs in these populations. The main goal of Cardio-Oncology is to reduce the burden of CVDs in oncologic patients allowing them to receive the best antitumor therapy (chemotherapy, targeted molecular therapies, hormone therapy, immunotherapy or radiotherapy) with the lowest rate of side effects and treatment interruptions.
Consequently, the ESC created the Council of Cardio-Oncology in August 2018 as a multidisciplinary constituent body which encourages the prevention, early diagnosis and management of cancer therapy-related cardiovascular diseases.
Our aims are to bring together European & non-European specialists in the field and specialists from Oncology, Hematology, Radiotherapy and related disciplines to enhance the knowledge and the standard of care for Cardio-Oncology patients. We will work in line with all the ESC Strategic Pillars: Advocacy, Congresses, Research, Membership and Education.
Improving the prevention, diagnosis, treatment and management of cancer therapy-related cardiovascular diseases.
Membership is free.
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.